Home › Compare › ALFNF vs ABBV
ALFNF yields 18.18% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 8
Combined, ALFNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALFNF + ABBV for your $10,000?
Alfen N.V., through its subsidiaries, designs, engineers, develops, produces, and sells products, systems, and services related to the electricity grid. The company offers smart grid solutions, including secondary transformer substations, devices for grid automation, and proprietary back-end systems for remote management and control of electricity grids, as well as micro-grids, grid connections, and supplementary offerings for the greenhouse horticulture sector, EV fast-charging hubs, and solar PV farms. It also provides energy storage systems comprising modular energy storage systems for load balancing, peak shaving, grid frequency control, and energy trading solutions, as well as stationary and mobile battery energy storage solutions. In addition, the company offers smart and connected electric vehicle chargers for use at the home, office, and public locations, as well as an online management platform for charging infrastructure and standardized solutions for smart charging, load balancing, and charging hubs. It operates primarily in the Netherlands, Belgium, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden, the United Kingdom, and the rest of Europe. The company was founded in 1937 and is headquartered in Almere, the Netherlands.
Full ALFNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.